Journal of Ophthalmology / 2019 / Article / Tab 2

Clinical Study

Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis

Table 2

Comparison of secondary outcome measures.

ItemsGroupsV0V1V2V3V4

CFS scoreTreatment group6.02 ± 3.742.86 ± 2.832.52 ± 2.382.05 ± 2.230.67 ± 1.07<0.001
Control group6.14 ± 4.443.50 ± 2.823.82 ± 3.352.82 ± 2.921.14 ± 1.64<0.001
0.9150.3910.0780.2430.173

NIKBUTTreatment group7.38 ± 5.797.44 ± 4.149.14 ± 4.9710.71 ± 4.0412.07 ± 4.14<0.001
Control group7.10 ± 5.617.17 ± 4.168.73 ± 4.959.23 ± 4.0610.53 ± 4.480.085
0.8570.8030.7590.1680.175

OSDI scoreTreatment group35.38 ± 15.7622.08 ± 12.9416.03 ± 9.548.18 ± 8.016.89 ± 7.61<0.001
Control group44.76 ± 17.0631.62 ± 15.8922.32 ± 8.9714.84 ± 7.3212.05 ± 4.64<0.001
0.1300.0770.0810.0290.049

SITTreatment group7.31 ± 5.246.81 ± 4.497.93 ± 4.198.26 ± 3.918.93 ± 3.620.197
Control group8.36 ± 5.175.91 ± 2.717.77 ± 2.747.64 ± 3.058.09 ± 3.310.168
0.4450.3930.8750.5160.370

Classification of tear film lipid layerTreatment group2.67 ± 0.852.93 ± 0.872.71 ± 0.802.64 ± 0.912.45 ± 0.830.155
Control group2.86 ± 0.832.91 ± 0.752.59 ± 0.802.59 ± 0.672.45 ± 0.510.175
0.3770.9290.5610.8130.991

Meibomian gland dropout (upper eyelid)Treatment group2.14 ± 0.842.45 ± 0.632.60 ± 0.632.50 ± 0.632.38 ± 0.730.044
Control group2.59 ± 0.672.45 ± 0.672.55 ± 0.512.55 ± 0.602.41 ± 0.590.857
0.0350.9900.7500.7820.877

Meibomian gland dropout (lower eyelid)Treatment group2.17 ± 0.822.45 ± 0.552.64 ± 0.622.48 ± 0.712.57 ± 0.590.016
Control group2.82 ± 0.392.55 ± 0.512.73 ± 0.462.32 ± 0.722.68 ± 0.480.062
0.0010.5120.5740.4010.452

value of one-way repeated measure analysis of variance to compare data for each group at different time points; value of multivariate analysis to compare the treatment and control groups at a specific time point.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.